## FILTING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

Express Mail Label Number

20. 

Other items or information: Unexecuted Declaration and Power of Attorney

> \$ #


JANUARY 20, 2006

Date of Deposit

Form PTO-1390-MOD U. S. Department of Commerce Patent and Trademark Office (REV 10-96)		ATTORNEY'S DOCKET NUMBER									
	TRANSMITTAL LETTER TO 1	ON/4-33289A U.S. APPLICATION NO. (If known, see 37 CFR 1.5)									
	DESIGNATED/ELECTED O										
	CONCERNING A FILING U	101565453									
	NATIONAL APPLICATION NO.	PRIORITY DATE CLAIMED									
PCT/EP2004/008107   20 July 2004 (20.07.04)   21 July 2003 (21.07.03)   TITLE OF INVENTION											
COMBINATIONS OF A CATHEPSIN K INHIBITOR AND A BISPHOSPHONATE IN THE TREATMENT OF BONE											
METASTASIS, TUMOR GROWTH AND TUMOR-INDUCED BONE LOSS											
APPLICANT(S) FOR DO/EO/US ZIMMERMANN ET AL.											
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:											
1. ⊠ 2. □ 3. □ 4. ⊠	This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.										
5. 🖾	date.  A copy of the International Application as filed (35 U.S.C. 371(c)(2))										
6. □ 7. ⊠	<ul> <li>a.  is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b.  is has been transmitted by the International Bureau. (See Form PCT/IB/308)</li> <li>c.  is not required, as the application was filed in the United States Receiving Office (RO/US).</li> <li>A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> </ul>										
9. 🔲	d. ⊠ have not been made and will not be made.  A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).  An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)).  A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).										
Items 11. to 16. below concern document(s) or information included.											
11. 🗆	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.										
12. 🗌	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.										
13. 🛚	A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment.										
14. 🔲	An Application Data Sheet under 37 CFR 1.76.										
15. 🗌	A substitute specification.										
16. 🗌	A change of power of attorney and/or address letter.										
17. 🗌	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.										
18. 🗌	A second copy of the published International Application under 35 U.S.C. 154(d)(4).										
19. 🗌	A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).										

U.S. APPLICATION NO. (If known see 37 GFR 15) 4 1 INTERNATIONAL APPLICATION NO. ATTORNEY'S DO ON/4-3328						L.				
The following fees are submitted:							CALCULATIONS PTO USE			
•					ONLY	-				
21. 🛛 Basic national fee										
22. Examination Fee  If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)										
23. Search fee  If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority \$  If International Search Report was prepared and provided to the Office \$400  All other situations										
тс	OTAL OF 21, 22 AND 23 =				\$	900				
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.										
Total Sheets Extra sheets Num	ber of each additional 50 or		F	RATE						
41 - 100 = 0 /50 =	0	iber	X \$	250	\$					
Surcharge of \$130 for furnishing the oath of declaration later than  30 months from the earliest claimed priority date (37 CFR 1.492(e)).										
CLAIMS NUMBER FII	LED NUMBER EXTR		RA							
Total claims 7	- 20 = 0		<u>(                                    </u>	50	\$					
Independent claims 2 MULTIPLE DEPENDENT CLAIM(S) (if ap	-3 = 0	<u> </u>	<u>&lt; \$</u> ⊦ \$	200 360	\$					
MOETIFEE DEFENDERT GEAIN(O) (II ap	\$	900								
Reduction of 1/2 for filing by small entity, i										
filed (Note 37 CFR 1.9, 1.27, 1.28).							<del></del>			
Processing fee of \$130 for furnishing the English translation later than 30 months from the										
earliest claimed priority date (37 CFR 1.492(f)). +  TOTAL NATIONAL FEE =										
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied										
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property + TOTAL FEES ENCLOSED =										
						ount to funded	\$			
	<del></del>				cl	harged	\$			
a. A check in the amount of \$	to cover the abo	ove fees is	enclosed.	•						
b.   Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$900 to cover the above fees. A duplicate copy of this form is enclosed.										
c.   The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.										
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.										
Send all correspondence to the address associated with Customer No. 001095, which is currently:										
Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080  Ona A. Jackson Attorney for Applicants Reg. No. 48,152 (862) 778-7852										

CALL 1-800-222-1811 FOR PICKUR OR TRACKING OF ALL YOUR PACKAGE



or Call 1-800-222-1811